The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vrupparapalli Reddy & Vrupparapalli Pavani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Promoters Vupparapalli Chandrasekhar Reddy and Vupparapalli Pavani received 5,60,000 equity shares of Novelix Pharmaceuticals on 29 May 2026 by converting warrants allotted through a preferential issue. Chandrasekhar Reddy's direct holding rose from 15,70,733 shares (7.45%) to 21,30,733 shares (8.92%); Pavani's holding stayed at 7,25,000 shares (3.03%). Combined promoter-group holding increased from 10.89% to 11.95% of equity capital (13.69% on a fully diluted basis). Total equity capital expanded from Rs. 21.085 crore to Rs. 23.895 crore as warrants were converted.
This is a routine warrant-to-equity conversion by existing promoters, so it does not bring in fresh outside money or change control. Shareholders should note modest promoter holding has risen, which is mildly positive for confidence, but there is no direct impact on stock price.